Indivior Earnings Call: Profits Surge as SUBLOCADE Leads

Indivior plc ((INDV)) has held its Q4 earnings call. Read on for the main highlights of the call.

Indivior’s latest earnings call struck a distinctly positive tone as management celebrated record company and SUBLOCADE revenues alongside sharp profitability gains. Executives balanced this upbeat narrative with acknowledgment of pressures in legacy products, restructuring costs, and dependence on a single key growth engine, but framed 2026 as a year of disciplined expansion and cash generation.

Record Revenue Growth Underpins the Quarter

Indivior reported total net revenue of $1.24 billion for 2025, a 4% increase versus 2024 despite headwinds from older products. Fourth quarter momentum was particularly strong, with net revenue jumping 20% year‑over‑year to $358 million, underscoring the strength of the company’s core addiction‑treatment franchise.

SUBLOCADE Solidifies Its Role as Growth Engine

SUBLOCADE delivered record net revenue of $856 million in 2025, up 13% year‑on‑year, with Q4 net revenue climbing 30% to $252 million. Dispense volume rose 7% for the year and 12% in Q4, and management now guides SUBLOCADE revenue to $905–$945 million in 2026, implying about 8% growth at the midpoint.

Commercial Momentum and Impact of DTC Campaign

Commercial metrics showed accelerating traction, with new patient starts in Q4 up 25% year‑over‑year and active prescribers, including higher‑volume ones, rising in the mid‑teens. The “Move Forward in Recovery” campaign appears to be working, driving a 60% jump in branded search, 70% more use of the provider‑finder tool, and CRM enrollments soaring to about 1,400 per month.

Adjusted EBITDA Surges with Expanding Margins

Profitability advanced faster than revenue, as adjusted EBITDA reached a record $428 million in 2025, up 20% with a 500‑basis‑point margin lift. The fourth quarter was particularly strong, with adjusted EBITDA up 91% to $142 million, and management now targets $535–$575 million in 2026, implying roughly a 48% margin.

Tight Cost Discipline Supports Earnings Leverage

The company’s margin gains are being driven by disciplined spending, with non‑GAAP operating expenses down 5% to $622 million in 2025. Indivior plans to cut these costs further in 2026 to $430–$450 million and has explicitly capped operating expenses at $450 million, signaling a firm commitment to efficiency.

Balance Sheet Strength and Capital Deployment Flexibility

Indivior further de‑risked its balance sheet by fully paying the remaining $295 million DOJ obligation, removing a legacy overhang. With year‑end gross cash and investments of $222 million, net leverage below 1x, expected 2026 operating cash flow of about $300 million, and a new $400 million buyback, the company has room for both debt management and selective deals.

Pipeline Positioned for Key Readouts and Focused BD

Two phase II trials wrapped up at the end of 2025, with data locks expected by the end of Q1 and top‑line results targeted for Q2, setting up important clinical milestones. On the business development front, management is focused on commercial‑stage assets with peak sales above $200 million, late‑2030s exclusivity, and clear differentiation to complement SUBLOCADE.

Guidance Tempered by SUBOXONE and Product Runoff

Despite strong SUBLOCADE trends, 2026 midpoint guidance implies a slight decline in total net revenue versus 2025, highlighting pressure elsewhere. Management cited ongoing U.S. SUBOXONE Film erosion from generics, lower rest‑of‑world revenue after portfolio optimization, and continued runoff of PERSERIS as key drags on the top line.

Gross‑to‑Net Volatility Clouds Comparisons

Reported 2025 revenue benefited from favorable gross‑to‑net dynamics, including about $19 million of gross and $10 million of net benefit in Q4 tied partly to a roughly two‑day inventory build. For the full year those effects totaled about $49 million, and management warned that similar gross‑to‑net tailwinds are unlikely to repeat, creating a potential headwind in 2026.

Restructuring Charges Reflect Ongoing Simplification

Indivior booked $120 million in charges in 2025 related to simplification efforts, including $55 million in Q4 for severance, lease exits, inventory write‑offs, and intangible write‑downs. The related cash costs were more modest at about $28 million for the year, but the restructuring underscores the scale of changes underway to refocus the portfolio.

R&D Pullback Adds Uncertainty to Long‑Term Pipeline

Non‑GAAP R&D spending fell 22% for the full year and 36% in Q4 as projects were reprioritized and the organization restructured. Moving the two phase II programs into phase III will depend not just on clinical data but also on manufacturing feasibility and payer‑validated evidence, adding uncertainty to future R&D levels and timelines.

International Optimization and Product Runoff Weigh on Growth

Outside the U.S., Indivior expects lower net revenue following optimization moves taken in 2025, reflecting a tighter focus on profitable markets. At the same time, the ongoing decline of products like PERSERIS will continue to drag on overall revenue growth, increasing the reliance on SUBLOCADE and future pipeline contributions.

Concentration Risk from Heavy Reliance on SUBLOCADE

SUBLOCADE has become the company’s primary growth driver, and management sees opportunity in the still‑low 9% penetration of long‑acting injectables. However, that concentration also poses risk if category expansion slows or payer access issues—such as hurdles between medical and pharmacy benefit channels—keep limiting broader adoption.

Debt Costs Shape Capital Allocation Strategy

Executives acknowledged that some of the company’s debt remains expensive and emphasized that reducing it is a key priority alongside the new repurchase plan. The balance between paying down debt, executing the $400 million buyback, and pursuing business development will hinge on market conditions, leaving some execution risk around capital allocation.

Guidance Points to Profits Rising Faster Than Sales

For 2026, Indivior forecasts total net revenue of $1.125–$1.195 billion, with SUBLOCADE revenue of $905–$945 million driven by an acceleration to mid‑teens U.S. dispense growth. Non‑GAAP operating expenses are projected at $430–$450 million and adjusted EBITDA at $535–$575 million, implying about a 48% margin and more than $300 million in operating cash flow to support debt reduction, buybacks, and selected deals.

Indivior’s earnings call painted a picture of a company leaning hard into its SUBLOCADE franchise while tightening costs and cleaning up its balance sheet. Investors will need to weigh the impressive margin expansion and cash‑generation outlook against product runoff, gross‑to‑net volatility, and concentration risk, but the upgraded profitability profile and capital flexibility set a constructive tone for the year ahead.